Ruzasvir/uprifosbuvir - Merck & Co

Drug Profile

Ruzasvir/uprifosbuvir - Merck & Co

Alternative Names: MK 3682C

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antivirals; Benzoxazines; Carbamates; Cyclopropanes; Esters; Imidazoles; Pyrrolidines; Thiazoles; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Dec 2017 Chemical structure information added
  • 29 Sep 2017 Discontinued - Phase-II for Hepatitis C (PO)
  • 09 May 2017 Phase-II clinical trials in Hepatitis C (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top